The purpose of the Gateway Group is to act as the expert advisory body to the YCN and its stakeholder organisations on access to new cancer medicines. This group will also link with the Tri-Network Cancer Drugs Group and through that group the Yorkshire and the Humber Specialised Commissioning Group (YHSCG). These recommendations do not constitute commissioning policies. They are supported by the YCN Management Board, and have been forwarded to YHSCG for agreement on regional commissioning policy.  Recommendations    document published downloaded Bevacizumab in combination with taxane-based chemotherapy for the 1st line treatment of metastatic breast cancer Feb 2010 94 Everolimus for the second-line treatment of patients with metastatic Renal Cell Cancer (mRCC) who are intolerant of or whose disease has progressed despite any prior VEGF receptor tyrosine kinase inhibitor therapy Feb 2010 110 Gefitinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK Feb 2010 119 Continued use of Trastuzumab following disease progression in metastatic breast cancer Feb 2010 98

	Membership
	Attendance
	Terms of Reference
	Recommendations
	Guidelines
	Education
	Research Network
	Links